Graph Database :: Data Schema
Graph Database :: Data Schema
-
DatabaseObject
- AbstractModifiedResidue [51759]
-
Affiliation
[335]
-
CatalystActivity
[37704]
- ControlReference [2729]
- ControlledVocabulary [14]
-
DatabaseIdentifier
[720031]
-
EntityFunctionalStatus
[683]
- Event [111908]
- ExternalOntology [958]
-
Figure
[873]
-
FunctionalStatus
[27]
-
FunctionalStatusType
[5]
- GO_Term [3004]
-
InstanceEdit
[124179]
- Interaction [54236]
-
NegativePrecedingEvent
[313]
-
Person
[156101]
-
PhysicalEntity
[389298]
-
Cell
[5]
-
Complex
[101725]
-
Drug
[1129]
-
ChemicalDrug
[1038]
-
ProteinDrug
[90]
-
RNADrug
[1]
-
ChemicalDrug
[1038]
- EntitySet [43152]
- GenomeEncodedEntity [237682]
-
OtherEntity
[347]
-
Polymer
[1504]
-
SimpleEntity
[3754]
-
Cell
[5]
- Publication [38727]
-
ReferenceDatabase
[148]
- ReferenceEntity [739543]
- Regulation [6937]
-
Summation
[20052]
- Taxon [391]
Entries: ReferenceTherapeutic
| Identifier | Name |
|---|---|
| 9709182 | Gemigliptin [PubChem Compound:11953153] |
| 9845135 | Gontivimab [PubChem Substance:472419397] |
| 9681739 | His-Leu-lopinavir [Guide to Pharmacology:9502] |
| 9687421 | Hydroxychloroquine(2+) [COMPOUND:78435478] |
| 9682037 | I-432 [Guide to Pharmacology:10733] |
| 9734397 | IFN-α2 [Guide to Pharmacology:4960] |
| 9734427 | IFN-α2b (recombinant human) [Guide to Pharmacology:8338] |
| 9696196 | IFN-β1a (recombinant human) [Guide to Pharmacology:8339] |
| 9696145 | IFN-β1b (recombinant human) [Guide to Pharmacology:8340] |
| 9687692 | IM-12 [Guide to Pharmacology:8017] |
| 9699406 | KW-2449 [Guide to Pharmacology:5691] |
| 9656550 | L-739,750 [Guide to Pharmacology:8030] |
| 9656552 | L-778123 [PubChem Compound:216453] |
| 9656555 | LB42908 [Guide to Pharmacology:8028] |
| 9707776 | LCB1 [Guide to Pharmacology:11236] |
| 9707837 | LCB3 [Guide to Pharmacology:11237] |
| 9733658 | LGK974 [Guide to Pharmacology:11167] |
| 9016674 | LY 294002 [Guide to Pharmacology:6004] |
| 9687666 | LY2090314 [Guide to Pharmacology:7958] |
| 9653104 | LY3009120 [Guide to Pharmacology:8943] |
| 9687694 | Li+ [Guide to Pharmacology:5212] |
| 9724541 | Linzagolix [PubChem Compound:16656889] |
| 9845204 | Lumicitabine [PubChem Compound:89658382] |
| 9683566 | MI-1148 [Guide to Pharmacology:8601] |
| 9016667 | MK-2206 [Guide to Pharmacology:7945] |
| 9735981 | MK-2461 [Guide to Pharmacology:7962] |
| 9684618 | MK-571 [Guide to Pharmacology:10346] |
| 9657500 | MK-8353 [Guide to Pharmacology:9974] |
| 9696138 | MP-A08 [Guide to Pharmacology:10219] |
| 9727118 | MRE-269 [Guide to Pharmacology:5852] |
| 9766609 | MS023 [Guide to Pharmacology:8955] |
| 9709458 | Methoxy polyethylene glycol-epoetin beta [PubChem Substance:347910408] |
| 9700709 | Methsuximide [PubChem Compound:6476] |
| 9686794 | N-ethyl-1-deoxynojirimycin [Guide to Pharmacology:4586] |
| 9704074 | N-methyl scopolamine [Guide to Pharmacology:316] |
| 9626127 | NS-49 [Guide to Pharmacology:481] |
| 9699598 | NVP-TAE684 [Guide to Pharmacology:5714] |
| 9845134 | Nirsevimab [PubChem Substance:472418861] |
| 9735988 | OMO-1 [Guide to Pharmacology:10507] |
| 9657498 | PD 0325901 [Guide to Pharmacology:7935] |
| 9603953 | PD173074 [Guide to Pharmacology:5037] |
| 9731193 | PF-00835231 [Guide to Pharmacology:11250] |
| 9756020 | PF-06873600 [Guide to Pharmacology:10426] |
| 9735953 | PHA-665752 [Guide to Pharmacology:5700] |
| 9603949 | PLX-4720 [Guide to Pharmacology:5703] |
| 9845100 | Palivizumab [PubChem Substance:472423423] |
| 9648873 | Palmostatin B [PubChem Compound:45100481] |
| 9708269 | Piclamilast [PubChem Compound:154575] |
| 9713821 | Platinum, amminedichloro(2-methylpyridine)-, (SP-4-3)- (SP-4-3)-Amminedichloro(2-methylpyridine)platinium [PubChem Compound:177358] |
| 9611286 | R-138727 [Guide to Pharmacology:1771] |
| 9754329 | R547 [Guide to Pharmacology:5707] |
| 9754354 | RGB-286638 [Guide to Pharmacology:7744] |
| 9657495 | RO 5126766 [PubChem Compound:16719221] |
| 9695924 | ROMe [Guide to Pharmacology:6625] |
| 9845096 | Rilematovir [PubChem Compound:118892432] |
© 2024 Reactome
